The Oxford University/AstraZeneca coronavirus vaccine is up to 90 per cent effective and can be stored safely in a standard fridge in another huge boost for the fight against Covid-19, preliminary results have revealed today.
The life-saving jab is viewed as Britain’s best chance of mass-inoculation of the population by the end of spring because Boris Johnson has ordered 100million doses.
Vaccines developed by Pfizer and Moderna in the US have showed 95 per cent protection – but both have to be stored between minus 75C and minus 20C and are up to £20 more expensive per jab.
Oxford University/AstraZeneca said today they have found no serious Covid-19 cases among any of 20,000 people who received the jab in the UK and Brazil.
The trials found that the jab is 90 per cent effective at fighting the killer virus when administered as a half dose first and then a full dose a month later. This drops to 62 per cent when someone is given two full doses a month apart.
In a statement, Professor Andrew Pollard, director of the Oxford Vaccine Group and chief investigator of the Oxford Vaccine Trial, said:
‘These findings show that we have an effective vaccine that will save many lives. Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply.
‘Today’s announcement is only possible thanks to the many volunteers in our trial, and the hard working and talented team of researchers based around the world.’
His colleague, Professor Sarah Gilbert, Professor of Vaccinology at the University of Sarah Gilbert, professor of vaccinology at the University of Oxford, said: ‘The announcement today takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by (Covid-19).
‘We will continue to work to provide the detailed information to regulators. It has been a privilege to be part of this multi-national effort which will reap benefits for the whole world.’
The UK has placed orders for 100 million doses of the Oxford vaccine – enough to vaccinate most of the population – with rollout expected in the coming weeks if the jab is approved.
It also has orders for 40 million doses of a jab from Pfizer and BioNTech, which has been shown to be 95% effective. Another jab from Moderna is 95% effective, according to trial data.
Business Secretary Alok Sharma said the results of an interim analysis of the University of Oxford and AstraZeneca’s coronavirus vacccine candidate were ‘very promising’.
The UK has placed orders for 100 million doses of the Oxford vaccine – enough to vaccinate most of the population – with rollout expected in the coming weeks if the jab is approved.
It also has orders for 40 million doses of a jab from Pfizer and BioNTech, which has been shown to be 95% effective.
Another jab from Moderna is 95% effective, according to trial data.
He tweeted: ‘Very promising data from the Oxford/AstraZeneca Phase III clinical trials. We are on the cusp of a huge scientific breakthrough that could protect millions of lives. The UK has secured early access to 100m doses of their vaccine – on top of 255m doses from other developers.’
AstraZeneca chief executive Pascal Soriot, said: ‘Today marks an important milestone in our fight against the pandemic. This vaccine’s efficacy and safety confirm that it will be highly effective against Covid-19 and will have an immediate impact on this public health emergency.
‘Furthermore, the vaccine’s simple supply chain and our no-profit pledge and commitment to broad, equitable and timely access means it will be affordable and globally available, supplying hundreds of millions of doses on approval.’
